Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
about
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.Design Issues in Randomized Clinical Trials of Maintenance Therapies.Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerCeritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses.Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.Surrogate endpoints for overall survival in lung cancer trials: a review.Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?A framework for understanding and targeting residual disease in oncogene-driven solid cancers.Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors.Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trialsHealth-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer.On the relationship between tumour growth rate and survival in non-small cell lung cancer.FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer.Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.Contrast-enhanced magnetic resonance imaging with a novel nano-size contrast agent for the clinical diagnosis of patients with lung cancer.
P2860
Q36334253-25A85854-7635-46DE-9C0B-0DA6132476BCQ36848078-2EAF2C45-C961-4DFE-9CC4-61513ABBC767Q37162291-EE89381E-93C2-4845-BCAB-1F3C2E87967FQ37393234-EA1385F2-B013-4B26-9631-BF2896D57718Q38638022-15EB34DF-E0ED-4236-A42F-B32107B9204FQ38670719-25AAC471-410A-4615-8767-DE3BC5700D9AQ38691539-6320BAB6-E642-4948-92EB-DA720A741C68Q38721743-7F7E6558-031D-404C-8DAD-2F69790E99F3Q38730533-DD72C234-D192-4287-B89C-30BCC23BF1A4Q38793230-FE13BC48-E5E1-4463-B6EB-62254481EB07Q38841987-7248F19A-3770-47F7-B860-86C286E21556Q38895586-718E8F51-EE74-42B6-B0EA-647D5416A7B8Q39295492-80619613-B376-44D5-85B6-DE9D2E04D0EFQ39819599-76F4992B-33D5-4C90-8143-8EDE38C4C98FQ39969335-AE10CF04-2DC8-46DD-9049-6F7B30EA1412Q40824695-1F98C7F9-0517-4404-AAD2-0D60B5195610Q40996798-6E3B5CD9-26BD-49DB-97C5-F703C6BC4F5BQ41848070-B9BD8F85-84FE-47DE-871B-202737C2D05AQ41908997-A2661DB5-2774-42C3-8083-1B41E23291DAQ42281334-DEABD134-DECF-45D6-B103-713A7DE30AFCQ42319246-0FFD8E5C-FDF4-4292-9ADF-698BFBC48A51Q42700668-E339989B-2A76-429A-B388-061ACB8B941AQ47129493-D23E35E9-DBE4-4118-9C37-6E7DD4C6A7C7Q47151204-DD9B842A-C692-45AF-861F-D51E1277F92CQ47307357-66EE8E82-614F-43CD-8494-E27CC9F57BB0Q49842796-AD48F604-4EB8-4627-8D20-FAEFA742D0FDQ50042729-CE437211-3696-4F93-B4D5-0295FED7D2A8Q50089402-1E91EA4E-41C6-4DDD-8420-6BA3EF0E3744Q50223635-98896E86-7031-4123-8A54-8B8433C65E2FQ50304177-C7212DEB-D7D9-4BDD-A0FD-AD0F758437C6Q50529551-67E8F0DC-3A1E-4FCE-AF19-FE805B8F3908Q52602395-B9008033-B087-4C08-94F5-73F82F2F155FQ52673089-601BA328-3170-4C5F-98F5-3EDC7FA206C7Q53001245-02C8673F-52A1-4146-9E93-02B6F22CD367Q53717818-A0EF9342-DCA9-4B2C-B750-9E8C8FB39BEFQ55072826-68A712AB-B120-46FF-A87D-D3D956A86525
P2860
Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Overall response rate, progres ...... el and patient-level analyses.
@ast
Overall response rate, progres ...... el and patient-level analyses.
@en
type
label
Overall response rate, progres ...... el and patient-level analyses.
@ast
Overall response rate, progres ...... el and patient-level analyses.
@en
prefLabel
Overall response rate, progres ...... el and patient-level analyses.
@ast
Overall response rate, progres ...... el and patient-level analyses.
@en
P2093
P2860
P356
P1476
Overall response rate, progres ...... el and patient-level analyses.
@en
P2093
Dickran Kazandjian
Gideon M Blumenthal
Lijun Zhang
Patricia Keegan
Rajeshwari Sridhara
Richard Pazdur
Shenghui Tang
Stella W Karuri
P2860
P304
P356
10.1200/JCO.2014.59.0489
P407
P50
P577
2015-02-09T00:00:00Z